1. HBW Insight
  2. >>Supply Chain

J&J Full Steam Ahead On Separating Consumer Business While Inflation, Pandemic Slow Results

 
• By Malcolm Spicer

While target date for spinning out consumer business into publicly traded company remains some time in 2023, J&J includes additional details on separation timetable with its 2021 full-year and fourth-quarter results.

• Source: Alamy

Inflationary pressures as well as the COVID-19 pandemic’s continuing impact on transportation and supplies are obvious in Johnson & Johnson’s latest consumer health business results, its plans to raise prices for products and its forecast for 2022.

The influence of increasing costs coupled with shipping delays and labor shortages isn’t reaching its plans to separate the consumer business, which makes and markets oral, personal and baby care

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 
• By Malcolm Spicer

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

Rapidly Changing Market Demands Quick Study From Consumer Health, Personal Care Marketers

 
• By Malcolm Spicer

“It is shifting so quickly. It's shifting underneath our feet,” says NielsenIQ wellness VP Sherry Frey. Even comparing the past year to the preceding eight, “it's just accelerating quicker and quicker, and one of the biggest areas is online.”

China Distribution Disruption Drags Kenvue Results

 
• By Malcolm Spicer

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

Tariff War Should Steer US Firms To Mapping Out North American Supply Chains

 
• By Malcolm Spicer

Supplies from Mexico and Canada could become even more important to US firms as well as more reliable than their current systems, says Rob Handfield, Bank of America distinguished professor of supply chain management at NC State.

More from HBW Insight

US FDA Supplement Office Chief Eyes ‘Movement’ This Year On NDI Notifications Final Guidance

 
• By Malcolm Spicer

“We've made some progress and really hope to see some movement as we move forward this year,” says FDA Office of Dietary Supplement Programs director Cara Welch.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By David Ridley

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.